La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Cue Biopharma Croissance future

Future contrôle des critères 2/6

Cue Biopharma devrait augmenter ses bénéfices et ses revenus de 13.8% et de 62.3% par an respectivement, tandis que le BPA devrait croître de croître de 26.2% par an.

Informations clés

5.5%

Taux de croissance des bénéfices

15.8%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.5%
Taux de croissance des recettes	36.5%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	20 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug

Oct 04

Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

Sep 23

News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat

Aug 26

Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates

Aug 10

Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%

May 18

Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

May 12

Cue Biopharma: A First Assessment

May 11

Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Mar 19

Cue Biopharma: Too Long To Arrive At Topline Trial Data

Feb 23

We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth

Nov 04

Cue Biopharma doses first patient in trial for CUE-101 in head and neck cancer

Jun 10

Companies Like Cue Biopharma (NASDAQ:CUE) Are In A Position To Invest In Growth

Jun 07

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:CUE - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	20	-35	N/A	N/A	3
12/31/2025	10	-39	N/A	N/A	4
12/31/2024	11	-40	N/A	N/A	4
6/30/2024	8	-47	-39	-39	N/A
3/31/2024	7	-50	-39	-39	N/A
12/31/2023	5	-51	-40	-40	N/A
9/30/2023	4	-52	-40	-40	N/A
6/30/2023	2	-52	-39	-39	N/A
3/31/2023	0	-52	-41	-41	N/A
12/31/2022	1	-53	-42	-42	N/A
9/30/2022	9	-47	-42	-42	N/A
6/30/2022	12	-49	-42	-42	N/A
3/31/2022	14	-46	-39	-39	N/A
12/31/2021	15	-44	-40	-39	N/A
9/30/2021	7	-47	-36	-35	N/A
6/30/2021	5	-44	-38	-36	N/A
3/31/2021	4	-44	-35	-33	N/A
12/31/2020	3	-45	-33	-32	N/A
9/30/2020	4	-43	-32	-32	N/A
6/30/2020	4	-40	-34	-33	N/A
3/31/2020	4	-38	-33	-33	N/A
12/31/2019	3	-37	-31	-31	N/A
9/30/2019	3	-39	-28	-28	N/A
6/30/2019	2	-45	-26	-25	N/A
3/31/2019	2	-43	-26	-25	N/A
12/31/2018	1	-39	-28	-26	N/A
9/30/2018	1	-38	-26	-24	N/A
6/30/2018	0	-30	-23	-22	N/A
3/31/2018	N/A	-27	N/A	-18	N/A
12/31/2017	N/A	-23	N/A	-12	N/A
9/30/2017	N/A	-16	N/A	-12	N/A
6/30/2017	N/A	-13	N/A	-10	N/A
3/31/2017	N/A	-10	N/A	-8	N/A
12/31/2016	N/A	-8	N/A	-6	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: CUE devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: CUE devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: CUE devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de CUE ( 62.3% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de CUE ( 62.3% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de CUE devrait être élevé dans 3 ans

Cue Biopharma Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Consensus estimates of losses per share improve by 20%

Price target decreased by 15% to US$8.00

Consensus revenue estimates increase by 17%

Consensus EPS estimates fall by 20%

Consensus revenue estimates decrease by 25%

Consensus revenue estimates decrease by 91%, EPS upgraded

Recent updates

Cue Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

New major risk - Share price stability

Cue Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

Cue Biopharma, Inc. Appoints Lucinda Warren as Chief Business Officer

Consensus estimates of losses per share improve by 20%

Cue Biopharma Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Cue Biopharma Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 15% to US$8.00

Cue Biopharma, Inc.(NasdaqCM:CUE) dropped from Russell Small Cap Completeness Index

Cue Biopharma, Inc. Appoints Michael J. Fox to the Board of Directors and the Compensation Committee

Consensus revenue estimates increase by 17%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Cue Biopharma, Inc., Annual General Meeting, Jun 05, 2024

Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money

New major risk - Revenue and earnings growth

Consensus EPS estimates fall by 20%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?

Consensus revenue estimates decrease by 25%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and Cue-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023

New minor risk - Share price stability

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®?

Cue Biopharma, Inc. Announces Resignation of Aaron Fletcher as Member of the Board of Directors, Effective October 9, 2023

Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Cue Biopharma, Inc. Presents Positive Data Update from Ongoing Phase 1 Trials of Cue-101 for Recurrent/Metastatichpv+ Head and Neck Squamous Cell Carcinoma At the 2023 American Society of Clinical Oncology Annual Meeting

Consensus revenue estimates decrease by 91%, EPS upgraded

Cue Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $17.6 million.

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Consensus revenue estimates fall by 24%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Cue Biopharma, Inc. Announces the Appointment of Rafi Ahmed to its Scientific Advisory Board

Cue Biopharma, Inc. Announces Executive Changes

Consensus forecasts updated

Cue Biopharma, Inc. announced that it expects to receive $29.999992 million in funding

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cue Biopharma, Inc. Presents New Positive Data from Ongoing Phase 1 Trial of Cue-101 in Combination with Keytruda for Recurrent/Metastatic Hpv+ Head and Neck Cancer At the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Cue Biopharma Grants FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug

Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat

Consensus revenue estimates fall by 50%

Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms’ Tumor 1 (WT1) - Expressing Cancers

Consensus revenue estimates increase by 54%

Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cue Biopharma, Inc. Announces Resignation of Cameron Gray as Member of the Board of Directors and All Committees

Insider recently bought US$105k worth of stock

Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%

Consensus revenue estimates fall by 23%

Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

U.S. Food and Drug Administration Accepts Cue Biopharma, Inc Investigational New Drug Application

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Cue Biopharma: A First Assessment

Cue Biopharma, Inc., Annual General Meeting, Jun 09, 2022

Price target decreased to US$24.83

CEO & Director exercised options and sold US$157k worth of stock

Consensus forecasts updated

Price target decreased to US$26.29

Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cue Biopharma: Too Long To Arrive At Topline Trial Data

President & Chief Scientific Officer exercised options and sold US$173k worth of stock

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$0.34 loss in 3Q 2020)

We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth